PRIME time at the EMA
Nature Reviews Drug Discovery 16, 226 (2017).
doi:10.1038/nrd.2017.57
Author: Asher Mullard
The European Medicines Agency's PRIME scheme to accelerate the development of promising drugs that address unmet medical needs has enrolled 19 products in its first year, showing considerable overlap with FDA breakthrough therapy designees but also key differences.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
More News: Drugs & Pharmacology | European Medicines Agency (EMA)